Travere Therapeutics, Inc. (TVTX) — 8-K Filings

8-K Filings (17)

• 8-K Filing — May 11, 2026
• Travere Therapeutics Relocates Principal Executive Offices — Sep 10, 2025 Risk: low
  On September 10, 2025, Travere Therapeutics, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 3611 Valley
• Travere Therapeutics Announces Board Changes and Officer Appointments — May 16, 2025 Risk: low
  On May 15, 2025, Travere Therapeutics, Inc. filed an 8-K report detailing several key events. These include the departure of director Dr. John F. McDonald, the
• Travere Therapeutics Files 8-K, Changes Principal Office — May 15, 2025 Risk: low
  On May 15, 2025, Travere Therapeutics, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 3611 Valley Centr
• Travere Therapeutics Appoints New Chief Medical Officer — Apr 30, 2025 Risk: low
  On April 29, 2025, Travere Therapeutics, Inc. announced the appointment of Dr. Blake C. Roberts as Chief Medical Officer. Dr. Roberts, previously the Senior Vic
• Travere Therapeutics Files 8-K, Updates Corporate Address — Mar 17, 2025 Risk: low
  On March 17, 2025, Travere Therapeutics, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 3611 Valley Cen
• Travere Therapeutics Files 8-K on Operations and Financials — Feb 20, 2025 Risk: low
  On February 20, 2025, Travere Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition,
• Travere Therapeutics Files 8-K — Feb 11, 2025 Risk: low
  On February 11, 2025, Travere Therapeutics, Inc. filed an 8-K report. The filing indicates that the company is providing information under "Other Events." No sp
• Travere Therapeutics Files 8-K on Financials — Jan 13, 2025 Risk: low
  On January 13, 2025, Travere Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition,
• Travere Therapeutics Files 8-K — Nov 8, 2024 Risk: low
  Travere Therapeutics, Inc. filed an 8-K on November 8, 2024, reporting other events and financial statements. The company, formerly known as Retrophin, Inc., is
• Travere Therapeutics Relocates Principal Executive Offices — Sep 26, 2024 Risk: low
  On September 26, 2024, Travere Therapeutics, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 3611 Valley
• Travere Therapeutics Files 8-K for Financials — Sep 6, 2024 Risk: low
  On September 5, 2024, Travere Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's financial statements and exhibits, with no spe
• Travere Therapeutics Announces Board Changes and New CMO — May 13, 2024 Risk: medium
  On May 8, 2024, Travere Therapeutics, Inc. (TVTX) filed an 8-K detailing several key events. These include the departure of Director Dr. Philip J. Louis, the el
• Travere Therapeutics Files 8-K with Exhibits — Apr 24, 2024 Risk: low
  On April 24, 2024, Travere Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update
• Travere Therapeutics Files 8-K on Feb 23 for 'Other Events' — Feb 23, 2024 Risk: low
  Travere Therapeutics, Inc. filed an 8-K on February 23, 2024, reporting an "Other Event" and "Financial Statements and Exhibits." The filing indicates a current
• Travere Therapeutics Files 8-K on Financial Results — Feb 15, 2024 Risk: medium
  Travere Therapeutics, Inc. filed an 8-K on February 15, 2024, reporting on Item 2.02, Results of Operations and Financial Condition, and Item 9.01, Financial St
• Travere Therapeutics Files 8-K on Financial Condition — Jan 8, 2024
  Travere Therapeutics, Inc. filed an 8-K on January 8, 2024, to report an event related to its results of operations and financial condition. This filing, under

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX